Intellia Therapeutics
NTLA
292 hedge funds and large institutions have $938M invested in Intellia Therapeutics in 2025 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 97 increasing their positions, 87 reducing their positions, and 48 closing their positions.
44% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $23.4M
40% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 48
11% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 87
3% more funds holding
Funds holding: 283 → 292 (+9)
7.1% less ownership
Funds ownership: 97.05% → 89.95% (-7.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
48% less capital invested
Capital invested by funds: $1.8B → $938M (-$861M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$42.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$31.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.9M |
| 5 |
Renaissance Technologies
New York
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
-$71.2M |
| 2 |
Morgan Stanley
New York
|
-$50.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$47.4M |
| 4 |
Goldman Sachs
New York
|
-$38.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.5M |
NTLA Hedge Fund Activity: Q4 2025 in Review
292 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2025, worth a combined $938M — down 48% from $1.8B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new NTLA positions and 48 closed out — a net gain of 19 holders — while 97 added to existing stakes and 87 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $42.7M. The largest seller was Contrarius Group Holdings, cutting an estimated $71.2M.
- 292 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2025, up from 283 in Q3 2025.
- Funds reported $938M of Intellia Therapeutics stock for Q4 2025, down 48% quarter-over-quarter.
- 67 funds opened new Intellia Therapeutics positions in Q4 2025 and 48 closed out, a net change of +19 holders.
- The largest Intellia Therapeutics buyer in Q4 2025 was D.E. Shaw & Co, an estimated $42.7M added.
- The largest Intellia Therapeutics seller in Q4 2025 was Contrarius Group Holdings, an estimated $71.2M sold.
Based on aggregated 13F filings for Q4 2025.